Repertoire will obtain an upfront payment of $35m from Genentech, with the potential for up to $730m in additional milestones ...

USC researchers have developed an innovative type of cancer-fighting immune cell, the EchoBack CAR T-cell, that uses focused ...

When naive T cells encounter antigen-presenting cells (APCs), membrane and cytoplasmic molecules rearrange at the T cell–APC contact area to form the immune synapse. Finetti et al. now reveal an ...

Repertoire Immune Medicines will get $35 million upfront, and possibly $730 million more, in a deal to help Roche’s Genentech ...

Cambridge, USA-based biotech Repertoire Immune Medicines today announced a collaboration and license agreement with Genentech ...

Repertoire Immune Medicines Inc. has entered into a collaboration and license agreement with Genentech Inc., a member of the Roche Group, to discover and develop innovative T cell-targeted immune ...

Roche’s Genentech is betting on the Flagship Pioneering–founded company’s discovery platform called DECODE to find new ...

Immunological synapse (IS) formation is a key part of developing and sustaining immune responses against cancer and is necessary for T cells and NK cells to eliminate tumor cells. This webinar will ...

The immune system must be able to quickly attack invaders like viruses, while also ignoring harmless stimuli, or allergies ...

A study published in Science Advances shares new insights into how two of the most common types of chimeric antigen receptor (CAR) T cells kill cancer. Investigators from Baylor College of ...

Repertoire Immune Medicines has entered into a collaboration and license agreement with Genentech to discover and develop innovative T cell-targeted immune medicines.